Becton, Dickinson and Company

$146.95+0.00%(+$0.00)
TickerSpark Score
55/100
Mixed
76
Valuation
70
Profitability
40
Growth
60
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDX research report →

52-Week Range32% of range
Low $127.59
Current $146.95
High $187.35

Companywww.bd.com

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

CEO
Thomas E. Polen Jr.
IPO
1973
Employees
70,000
HQ
Franklin Lakes, NJ, US

Price Chart

+5.80% · this period
$185.39$158.90$132.41May 20Nov 18May 20

Valuation

Market Cap
$53.24B
P/E
36.24
P/S
2.49
P/B
1.71
EV/EBITDA
16.74
Div Yield
2.39%

Profitability

Gross Margin
46.48%
Op Margin
10.61%
Net Margin
5.33%
ROE
4.54%
ROIC
4.10%

Growth & Income

Revenue
$21.84B · 8.23%
Net Income
$1.68B · -1.58%
EPS
$5.84 · -0.68%
Op Income
$2.58B
FCF YoY
-13.09%

Performance & Tape

52W High
$187.35
52W Low
$127.59
50D MA
$153.40
200D MA
$154.47
Beta
0.28
Avg Volume
2.92M

Get TickerSpark's AI analysis on BDX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 8, 26Huffines Robert Lutherother210
May 8, 26Byington Carrie Lother105
May 7, 26Roque Vitorother1,721
Apr 27, 26Feld Michaelsell74
Apr 6, 26Neal Shana Carolother1,146
Mar 26, 26Feld Michaelsell75
Mar 16, 26Minnix Laneshaother7,492
Mar 16, 26Minnix Laneshaother0
Mar 2, 26Roque Vitorother931
Mar 2, 26Spikner Pamela L.other931

Our BDX Coverage

We haven't published any research on BDX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate BDX Report →

Similar Companies